Confluence Pharmaceuticals is developing novel therapeutic medications for neurological development disorders
Confluence Pharmaceuticals is developing novel therapeutic medications for neurological development disorders. The company's current focus is advancing a novel drug discovery that improves social and communication impairments for individuals with Autism Spectrum Disorders and Fragile X Syndrome.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 12, 2019 | Series Unknown | $200K | 1 |
![]() |
— | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
![]() |
Yes | Series Unknown |